Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbbVie (GB:0QCV)
LSE:0QCV
Holding GB:0QCV?
Track your performance easily
0QCV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$135.97 - $200.00
Previous Close$188.36
Volume1.40K
Average Volume (3M)21.55K
Market Cap
$333.42B
Enterprise Value$390.94B
Total Cash (Recent Filing)$13.16B
Total Debt (Recent Filing)$70.63B
Price to Earnings (P/E)63.0
Beta0.29
Next Earnings
Oct 30, 2024EPS Estimate
$2.92Last Dividend Ex-Date
Oct 15, 2024Dividend Yield3.29%
Share Statistics
EPS (TTM)2.99
Shares Outstanding1,766,343,745
10 Day Avg. Volume211
30 Day Avg. Volume21,547
Standard Deviation0.10
R-Squared0.00552
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)20.78
Price to Sales (P/S)5.99
Price to Cash Flow (P/CF)36.30
P/FCF Ratio33.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.11
Enterprise Value/Gross Profit11.53
Enterprise Value/Ebitda21.69
Forecast
1Y Price Target
$203.44Price Target Upside8.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
AbbVie News
Bulls Say, Bears Say
Bulls Say
Drug Development And EfficacyAbbVie released positive topline efficacy and encouraging safety results from tavapadon’s fixed-dose monotherapy trial for early Parkinson’s Disease.
Market Position And StrategyABBV is a dominant player in the global aesthetics market.
Product Demand And Sales GrowthRinvoq and Skyrizi demand could drive guidance raise again.
Bears Say
Aesthetics PerformanceAesthetic softness is a worrying sign, and analysts remain below their long-term guidance.
Financial GuidanceThe company lowered 2024 aesthetics guidance to $5.5bn from $5.7bn.
Market CompetitionPD is a crowded market with many generic dopamine agonists available.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.08% Insiders
22.14% Mutual Funds
1.41% Other Institutional Investors
56.09% Public Companies and
Individual Investors
0QCV FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest share price was $135.97 and its highest was $200.00 in the past 12 months.
What is AbbVie’s market cap?
Currently, no data Available
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Oct 30, 2024 which is in 7 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Jul 25, 2024. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.566 by $0.084.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of $1.55 which represents an annual dividend yield of 3.29%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is $2.92.
How many shares outstanding does AbbVie have?
AbbVie has 1,766,343,800 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of $2.65 in its last earnings report, beating expectations of $2.566. Following the earnings report the stock price went up 3.205%.
Which hedge fund is a major shareholder of AbbVie?
Among the largest hedge funds holding AbbVie’s share is Diamond Hill Capital Management Inc. It holds AbbVie’s shares valued at 233M.
---
AbbVie Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$203.44 (8.00% Upside)
$203.44 (8.00% Upside)
Blogger Sentiment
Bullish
GB:0QCV Sentiment 96%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $12.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.80%
12-Months-Change
Fundamentals
Return on Equity
53.93%
Trailing 12-Months
Asset Growth
4.85%
Trailing 12-Months
Company Description
AbbVie
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
---
0QCV Earnings Call
Q2 2024
0:00 / 0:00
---
0QCV Net revenue Breakdown
48.12% Immunology
14.21% Neuroscience
12.59% Other Key Products
10.89% Oncology
14.19% Other
---
0QCV Stock 12 Month Forecast
Average Price Target
$203.44
▲(8.00% Upside)
Technical Analysis
Best Analysts Covering 0QCV
1 Year
1 Year Success Rate
14/15 ratings generated profit
1 Year Average Return
+18.68%
reiterated a buy rating 9 days ago
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 93.33% of your transactions generating a profit, with an average return of +18.68% per trade.
---